John Breitner, MD, has devoted his career to investigating factors that modify an individual’s risk of developing Alzheimer's Disease.

As a clinician, Johanne Renaud holds the title of medical chief for the youth section of the Douglas Institute’s Depressive Disorders Program.

Suzanne King is investigating  risk factors for schizophrenia, such as prenatal stress, obstetric complications, and cannabis use.

Natalie Grizenko is medical director with the mandate of integrating research, teaching and clinical excellence throughout the program.

Gustavo Turecki investigates the neurobiology of suicide, focusing on the role of genetic risk factors.

Jacques Tremblay is actively involved in quality assurance, and in improving the safety of medication use.

Hani Iskandar has been involved in clinical research projects in the fields of schizophrenia, mood disorders and pharmacology.  

Thomas Brown studies the development of psychosocial interventions to combat substance abuse.

Work from Rémi Quirion's lab has helped to characterize the roles of cholinergic synapses in Alzheimer Disease, neuropeptide Y in depression and learning, and calcitonin gene-related peptide (CGRP) in pain and opioid tolerance.

Opening - Parle-moi d'amour at the Wellington Centre from February 6 to March 13, 2014